DE102004005788A1 - Preparations containing Echinacea extracts and thiocyanate - Google Patents
Preparations containing Echinacea extracts and thiocyanate Download PDFInfo
- Publication number
- DE102004005788A1 DE102004005788A1 DE102004005788A DE102004005788A DE102004005788A1 DE 102004005788 A1 DE102004005788 A1 DE 102004005788A1 DE 102004005788 A DE102004005788 A DE 102004005788A DE 102004005788 A DE102004005788 A DE 102004005788A DE 102004005788 A1 DE102004005788 A1 DE 102004005788A1
- Authority
- DE
- Germany
- Prior art keywords
- thiocyanate
- preparation according
- echinacea
- spec
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 title claims abstract description 30
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims description 39
- 235000020694 echinacea extract Nutrition 0.000 title description 3
- 235000014134 echinacea Nutrition 0.000 claims abstract description 35
- 230000002265 prevention Effects 0.000 claims abstract description 11
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 8
- 210000000214 mouth Anatomy 0.000 claims abstract description 7
- 206010052428 Wound Diseases 0.000 claims abstract description 6
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 6
- 239000000284 extract Substances 0.000 claims abstract description 6
- 210000004261 periodontium Anatomy 0.000 claims abstract description 6
- 210000001215 vagina Anatomy 0.000 claims abstract description 6
- 230000036448 vitalisation Effects 0.000 claims abstract description 6
- 230000029663 wound healing Effects 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 230000000771 oncological effect Effects 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 230000004215 skin function Effects 0.000 claims abstract description 5
- 239000002537 cosmetic Substances 0.000 claims abstract description 4
- 230000036541 health Effects 0.000 claims abstract description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 3
- 210000004400 mucous membrane Anatomy 0.000 claims abstract description 3
- 244000133098 Echinacea angustifolia Species 0.000 claims description 29
- -1 ovules Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 11
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 6
- 244000062730 Melissa officinalis Species 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 241000196324 Embryophyta Species 0.000 claims description 4
- 244000141009 Hypericum perforatum Species 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 claims description 4
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 claims description 4
- 150000003567 thiocyanates Chemical class 0.000 claims description 4
- 235000010654 Melissa officinalis Nutrition 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000000419 plant extract Substances 0.000 claims description 3
- 229940116357 potassium thiocyanate Drugs 0.000 claims description 3
- ALWXETURCOIGIZ-UHFFFAOYSA-N 1-nitropropylbenzene Chemical compound CCC([N+]([O-])=O)C1=CC=CC=C1 ALWXETURCOIGIZ-UHFFFAOYSA-N 0.000 claims description 2
- 241000546188 Hypericum Species 0.000 claims description 2
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000007124 immune defense Effects 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000002324 mouth wash Substances 0.000 claims description 2
- 229940051866 mouthwash Drugs 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
- 230000036074 healthy skin Effects 0.000 claims 1
- 150000007530 organic bases Chemical class 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 abstract description 2
- 241000258180 Echinacea <Echinodermata> Species 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 13
- 206010057249 Phagocytosis Diseases 0.000 description 9
- 240000004530 Echinacea purpurea Species 0.000 description 8
- 210000003714 granulocyte Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000028993 immune response Effects 0.000 description 6
- 230000008782 phagocytosis Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 230000003308 immunostimulating effect Effects 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 4
- 244000170506 Etlingera solaris Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 235000017807 phytochemicals Nutrition 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229930000223 plant secondary metabolite Natural products 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 240000007311 Commiphora myrrha Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001295925 Gegenes Species 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 241001127637 Plantago Species 0.000 description 1
- 102100038567 Properdin Human genes 0.000 description 1
- 108010005642 Properdin Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010064093 Suggestibility Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241000245665 Taraxacum Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000001080 anti-teratogenic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- FNEZBBILNYNQGC-UHFFFAOYSA-N methyl 2-(3,6-diamino-9h-xanthen-9-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1C2=CC=C(N)C=C2OC2=CC(N)=CC=C21 FNEZBBILNYNQGC-UHFFFAOYSA-N 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 210000000680 phagosome Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000015323 positive regulation of phagocytosis Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000007391 self-medication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Die Erfindung betrifft kosmetische oder pharmazeutische Zubereitungen, enthaltend Auszüge aus einer oder mehreren Echinacea spec. und Thiocyanat in Form eines oder mehrerer Salze und/oder Thiocyanat-Ionen freisetzender Verbindungen, zur Vitalisierung der Schleimhaut der Mundhöhle sowie des Zahnhalteapparates und zur Vorbeugung von entzündlichen Erkrankungen der Mundhöhle und des Zahnhalteapparates, zur Pflege und Vorbeugung entzündlicher Erkrankungen der Vagina, der Förderung der Wundheilung bei oberflächlichen Wunden, der Vitalisierung sowie der Gesunderhaltung der Haut bei normaler oder gestörter Hautfunktion und/oder zur Vitalisierung des Organismus bei dessen Leistungen bei der Immunabwehr, insbesondere für die Vorbeugung von onkologischen Erkrankungen.The invention relates to cosmetic or pharmaceutical preparations containing extracts of one or more Echinacea spec. and thiocyanate in the form of one or more salts and / or thiocyanate ion-releasing compounds, for revitalizing the mucous membrane of the oral cavity and the periodontium apparatus and for preventing inflammatory diseases of the oral cavity and the periodontium, for the care and prevention of inflammatory diseases of the vagina, the promotion of Wound healing in superficial wounds, the vitalization and health of the skin with normal or impaired skin function and / or vitalization of the organism in its performance in the immune system, in particular for the prevention of oncological diseases.
Description
Gegenstand der Erfindung sind Zubereitungen enthaltend Echinacea-Auszüge und Thiocyanat.object The invention relates to preparations containing echinacea extracts and thiocyanate.
Echinacea purpurea (L.) ist eine Pflanze von hohem pharmakologischem Interesse (Bauer, R.: Pflanzliche Immunstimulanzien in der Selbstmedikation. Pharmazie in unserer Zeit 27(4), 144–157, (1998)).Echinacea purpurea (L.) is a plant of high pharmacological interest (Bauer, R .: Plant immune stimulants in self-medication. Pharmacy in our time 27 (4), 144-157, (1998)).
Zubereitungen aus Echinacea purpurea werden in Deutschland seit Jahrzehnten als Immunstimulantien eingesetzt. Das gilt innerlich für rezidivierende Infekte der Atemwege und der ableitenden Harnwege, äußerlich bei schlecht heilenden Wunden. Auch andere Echinacea spec. beispielsweise E. angustifolia oder E. pallida werden als potentielle Ausgangsdrogen für immunstimulierende Zubereitungen eingesetzt.preparations from Echinacea purpurea have been used in Germany for decades as Immunostimulants used. This applies internally for recurrent Infections of the respiratory and urinary tract, external for badly healing wounds. Also other Echinacea spec. for example E. angustifolia or E. pallida are considered potential starting drugs for immunostimulating Preparations used.
Eine Übersicht über die Pharmakognosie und Pharmakologie von Echinacea-Zubereitungen findet sich im Stand der Technik. Im Einzelnen wird eine Stimulierung der Phagozytose, eine Induktion von Zytokinen unter Einfluss von Echinacea-Presssäften nachgewiesen. Ebenfalls war eine antivirale Aktivität von Echinacea-Zubereitungen feststellbar. Unerwünschte Nebenwirkungen wurden nicht beobachtet. Allerdings gibt es bei Personen mit allergischer Diathese unter Umständen entsprechende Reaktionen.An overview of the Pharmacognosy and pharmacology of echinacea preparations can be found in the prior art. In particular, a stimulation of phagocytosis, demonstrated induction of cytokines under the influence of Echinacea press juices. Also was an antiviral activity of echinacea preparations ascertainable. unwanted Side effects were not observed. However, there are people with allergic diathesis may have appropriate reactions.
Eine Patientenbewertung über die Wirksamkeit von Presssaft aus Echinacea purpurea durch 60 Probanden, sowie einer Kontroll-Gruppe von ebenfalls 60 Personen, die Placebo erhielten, ergab bei einer Anwendung gegen Atemwegsinfektionen günstige Ergebnisse. Durch die Anwendung des Echinacea-Presssaftes waren die Beschwerden 4 Tage schneller abgeklungen als bei der Placebobehandlung.A Patient evaluation about the effectiveness of press juice from Echinacea purpurea by 60 volunteers, as well as a control group of likewise 60 persons, the placebo obtained favorable results when used against respiratory infections. By the application of the Echinacea press juice the complaints were Decayed 4 days faster than placebo treatment.
In
- – Stimulierung der Granulozyten und Makrophagen-Phagozytose
- – Erhöhte Freisetzung von Effektorsubstanzen aus Granulozyten und Makrophagen, beispielsweise Interferon, Interleukin 1 und Tumornekrosefaktor
- – Erhöhung des Properdinspiegels
- – Antivirale Wirkung gegen Influenza Virus, Herpes Virus pro genitalis, sowie Vesicular-Stomatitis-Virus.
- - Stimulation of granulocytes and macrophage phagocytosis
- Increased release of effector substances from granulocytes and macrophages, for example interferon, interleukin 1 and tumor necrosis factor
- - Increase of properdin level
- Antiviral activity against influenza virus, genital herpes virus, and vesicular stomatitis virus.
Speziell für Echinacea purpurea (L.) wird die in Patientenstudien aufgezeigte paraimmunische Aktivität wie folgt wiedergegeben:
- – Erhöhung der Granulozyten-Phagozytose-Aktivität
- – Steigerung der Lymphozyten-Aktivität im NK-Zell-Test (NK-Zellen = knochenmarkabhängige natürliche Killerzellen)
- – Induktion einer Erhöhung der Leukozytenzahl
- – Steigerung der zellvermittelten Immunität.
- - increase in granulocyte phagocytosis activity
- - Increased lymphocyte activity in the NK cell test (NK cells = bone marrow-dependent natural killer cells)
- - induction of an increase in the leucocyte count
- - Increasing cell-mediated immunity.
WO 98/42188 beschreibt Zusammensetzungen, die neben Benzalkoniumchlorid Phytochemikalien aus Echinacea und Commiphora myrrha enthalten und gegen HIV und mikrobielle Infektionen wirksam sein sollen.WHERE 98/42188 describes compositions in addition to benzalkonium chloride Phytochemicals from Echinacea and Commiphora myrrha contain and to be effective against HIV and microbial infections.
WO 98/11778 beschreibt Zusammensetzungen, die neben Benzalkoniumchlorid Phytochemikalien aus Echinacea enthalten, zur Anwendung gegen Herpes und andere mikrobielle Infektionen.WHERE 98/11778 describes compositions in addition to benzalkonium chloride Contain phytochemicals from Echinacea, for use against herpes and other microbial infections.
Unter den anorganischen Salzen kommt den Thiocyanat-Ionen eine besondere Stellung als essentieller Faktor der Zelltätigkeit zu. Sie wirken auf das Transmembranpotential der Zellmembran und bewirken eine bioelektrische Hyperpolarisation.Under The inorganic salts are the thiocyanate ions a special Position as an essential factor of cell activity. They work the transmembrane potential of the cell membrane and cause a bioelectric Hyperpolarization.
Das gilt nicht nur für die Zellmembran als Ganzes, sondern auch für die Zellkompartimente. Ferner beeinflussen sie die Aktivität zahlreicher Enzyme. Sie wirken fördernd auf die Zellproliferation.The not only applies to the cell membrane as a whole, but also for the cell compartments. Further they influence the activity numerous enzymes. They have a positive effect on cell proliferation.
Hieraus resultieren biologisch und medizinisch wichtige Auswirkungen, insbesondere eine Förderung der verschiedenen Stufen der Immunantwort von der Phagozytose bis zur humoralen Antikörperbildung.From this result biologically and medically important effects, in particular a promotion of various stages of the immune response from phagocytosis to humoral antibody production.
Ferner kommt den Thiocyanat-Ionen eine besondere Bedeutung im H2O2-Thiocyanat-Peroxidase-System zu.Furthermore, the thiocyanate ions are of particular importance in the H 2 O 2 thiocyanate peroxidase system.
Das gilt sowohl für den Ablauf der Phagozytose, als auch für die lokalen Abwehrmechanismen auf den Körperoberflächen beispielsweise in der Mundhöhle und in der Vagina, besonders an den sogenannten Eintrittspforten für Krankheitserreger.The applies to both the course of phagocytosis, as well as local defense mechanisms on the body surfaces, for example in the oral cavity and in the vagina, especially at the so-called entry ports for pathogens.
Das gilt des weiteren für die antitoxische, antimutagene und antiteratogene Protektion der Zelle vor den Folgen von Gifteinwirkungen.The applies furthermore for the antitoxic, antimutagenic and antiteratogenic protection of Cell from the effects of toxins.
Als Resultante der Förderung der Zellproliferation und der Immunantwort wird durch Thiocyanat die Wundheilung verbessert. Es stellt einen Schutzfaktor zur Verhinderung von onkologischen Erkrankungen dar.When Resultant of promotion Cell proliferation and immune response is by thiocyanate the wound healing improves. It provides a protection factor to prevent of oncological diseases.
Der Erfindung lag die Aufgabe zugrunde, Zubereitungen bereitzustellen, die eine gegenüber dem Stand der Technik gesteigerte Immunstimulierung bewirken.Of the The invention had the object of providing preparations, the one opposite cause the state of the art increased immune stimulation.
Erfindungsgemäß hat sich herausgestellt, dass kosmetische oder pharmazeutische Zubereitungen von Echinacea-Pflanzen und Thiocyanat-Ionen sich in vorteilhafter Weise ergänzen, unter anderen in folgenden Eigenschaften:
- – Während Zubereitungen aus Echinacea purpurea sowie weiteren Echinacea spec. allein mehr oder weniger unspezifisch die Gewebsproliferation anregen, stellen Thiocyanat-Ionen allein einen natürlichen Proliferationsfaktor dar.
- – Der unspezifische Reiz von Echinacea spec. auf die Gewebe führt zu einer Leistungssteigerung der Abwehrmechanismen und der Zellproliferation.
- – Es wurde bereits auf die bekannten Angriffspunkte der Echinacea-Zubereitungen auf die Immunantwort hingewiesen. Es ist deutlich, dass die Thiocyanat-Ionen an gleichen Stellen der Immunantwort wirksam sind, so dass durch zwei verschiedene Mechanismen ein vorteilhafter Effekt entsteht.
- – Durch die Beteiligung der Thiocyanat-Ionen an den natürlichen Abwehrleistungen, beispielsweise am H2O2-Thiocyanat-Peroxidase-System, an der Phagozytose und weiteren Stufen der Immunantwort wird die lokale Abwehrsituation verbessert.
- - During preparations of Echinacea purpurea and other Echinacea spec. alone more or less nonspecific stimulate tissue proliferation, thiocyanate ions alone represent a natural proliferation factor.
- - The nonspecific allure of Echinacea spec. on the tissues leads to an increase in performance of defense mechanisms and cell proliferation.
- - It has already been pointed to the known targets of Echinacea preparations on the immune response. It is clear that the thiocyanate ions are effective at the same sites of the immune response, so that by two different mechanisms, an advantageous effect arises.
- - The involvement of thiocyanate ions in the natural defense, for example, the H 2 O 2 thiocyanate peroxidase system, the phagocytosis and other stages of the immune response, the local defense situation is improved.
Die vorgenannte Aufgabe wurde daher erfindungsgemäß gelöst durch kosmetische oder pharmazeutische Zubereitungen enthaltend Auszüge aus einer oder mehreren Echinacea spec. und Thiocyanat in Form eines oder mehrerer Salze und/oder Thiocyanat-Ionen freisetzender Verbindungen zur Vitalisierung der Schleimhaut der Mundhöhle sowie des Zahnhalteapparates und zur Vorbeugung von entzündlichen Erkrankungen der Mundhöhle und des Zahnhalteapparates, zur Pflege und Vorbeugung entzündlicher Erkrankungen der Vagina, der Förderung der Wundheilung bei oberflächlichen Wunden, der Vitalisierung sowie der Gesunderhaltung der Haut bei normaler oder gestörter Hautfunktion, und/oder zur Vitalisierung des Organismus bei dessen Leistungen bei der Immunabwehr, insbesondere für die Vorbeugung von onkologischen Erkrankungen.The The aforementioned object has therefore been achieved according to the invention by cosmetic or pharmaceutical Preparations containing extracts from one or more Echinacea spec. and thiocyanate in the form of a or more salts and / or thiocyanate ion releasing compounds to revitalize the mucous membrane of the oral cavity and the periodontium and for the prevention of inflammatory Diseases of the oral cavity and the periodontium, for the care and prevention of inflammatory Diseases of the vagina, promotion wound healing in superficial Wounds, the vitalization and the health of the skin normal or disturbed Skin function, and / or vitalization of the organism in its Services in the immune defense, in particular for the prevention of oncological Diseases.
Thiocyanat-Ionen, angewendet in physiologischen Konzentrationen, wie sie im Säugetier-Organismus und auf den Körperoberflächen vorkommen, haben bekanntermaßen keine Nebenwirkungen. Vielmehr wird erfindungsgemäß in vorteilhafter Weise die für den Organismus benötigte Menge an Thiocyanat-Ionen optimiert.Thiocyanate ions, applied in physiological concentrations, as in the mammalian organism and occur on the body surfaces, have known no side effects. Rather, the invention is advantageously Way for needed the organism Amount of thiocyanate ions optimized.
Beides, die Pflanzenpresssäfte und sonstigen Zubereitungen von Echinaceae purpureae herba bzw. weiteren Echinacea spec. und die Thiocyanat-Ionen sind Naturstoffe, wobei die letzteren auch synthetisch gewonnen werden.Both, the vegetable press juices and other preparations of Echinaceae purpureae herba or others Echinacea spec. and the thiocyanate ions are natural products, wherein the latter are also obtained synthetically.
Unter den Echinacea spec., die erfindungsgemäß Verwendung finden können, werden Echinaceae purpureae e herba recens, Echinaceae angustifoliae e radices und Echinacea purpurea Presssaft bevorzugt. Verwandte Arten, wie zum Beispiel E. pallida sind jedoch auch geeignet.Under the Echinacea spec., which can be used according to the invention are Echinaceae purpureae e herba recens, Echinaceae angustifoliae e radices and Echinacea purpurea pressed juice preferred. Related species, however, such as E. pallida are also suitable.
Die eingesetzten Thiocyanat-Salze sind bevorzugt ausgewählt aus: Kaliumthiocyanat, Natriumthiocyanat, Calciumthiocyanat, Ammoniumthiocyanat oder anderen anorganischen Thiocyanaten, thiocyansauren Salzen organischer Basen, insbesondere Guanidinhydrothiocyanat oder deren Gemischen. Es können jedoch auch pharmakologisch geeignete Thiocyanat-Donatoren, wie zum Beispiel Pflanzenzubereitungen, die aus glykosidischen Bindungen Thiocyanat in Freiheit setzen, eingesetzt werden.The Thiocyanate salts used are preferably selected from: Potassium thiocyanate, sodium thiocyanate, calcium thiocyanate, ammonium thiocyanate or other inorganic thiocyanates, thiocyanate salts organic Bases, in particular Guanidinhydrothiocyanat or mixtures thereof. It can but also pharmacologically suitable thiocyanate donors, such as for example, plant preparations derived from glycosidic bonds Thiocyanate be set free to be used.
Die erfindungsgemäßen Zubereitungen können in Form einer Mundspülung, eines Gels, einer Salbe oder als Zusatz in Inhalationsmitteln, insbesondere in Form von Sprays oder Dampfbädern hergestellt und wirksam eingesetzt werden. Entsprechende Zubereitungen können je nach Anwendungszweck in verschiedenen Darreichungsformen hergestellt und appliziert werden. Zubereitungen zur Pflege und Vorbeugung entzündlicher Erkrankungen der Vagina beispielsweise in Form von Spülungen, Cremes, Tabletten, Ovula, Zäpfchen und Kapseln, Zubereitungen zur Förderung der Wundheilung bei oberflächlichen Wunden in Form von Pudern, Cremes, Salben und/oder von mit der Zubereitung imprägnierten Spezialverbandstoffen. Zubereitungen zur Vitalisierung sowie Gesunderhaltung der Haut bei normaler und/oder gestörter Hautfunktion werden bevorzugt in Form von Salben, Pudern, Lotionen, Cremes und Hautölen hergestellt. Die Zubereitungen können auch als Zusatz zu Bädern auf Tensidbasis oder zu Ölbädern dienen. Die Erfindung umfasst ebenso Zubereitungen zur innerlichen Anwendung. Ferner dient das der Vitalisierung des Organismus und der Stimulierung der Leistung der Immunantwort. Das gilt auch für die Förderung der Abwehrleistungen des Organismus zur Vorbeugung von onkologischen Erkrankungen.The preparations according to the invention can in the form of a mouthwash, a gel, an ointment or as an additive in inhalants, in particular in the form of sprays or steam baths manufactured and used effectively. Appropriate preparations can depending on the application in different dosage forms produced and applied. Preparations for the care and prevention of inflammatory Diseases of the vagina, for example in the form of flushes, Creams, tablets, ovules, suppositories and capsules, preparations for the promotion wound healing in superficial Wounds in the form of powders, creams, ointments and / or with the preparation impregnated Special dressings. Preparations for revitalization and health maintenance Skin with normal and / or impaired skin function are preferred prepared in the form of ointments, powders, lotions, creams and skin oils. The preparations can also as an addition to baths surfactant-based or to serve oil baths. The invention also includes preparations for internal use. It also serves to vitalise the organism and stimulate the body Performance of the immune response. This also applies to the promotion of defense services of the organism for the prevention of oncological diseases.
Die vorteilhafte Wirkung der erfindungsgemäß hergestellten und oben beschriebenen Zubereitungen kann zusätzlich gesteigert werden, indem weitere Pflanzenauszüge, dabei insbesondere aus Melissa spec., wie beispielsweise Melissa officinalis (Melisse) und/oder Hypericum spec., wie beispielsweise Hypericum perforatum (Johanniskraut) enthalten sind.The advantageous effect of the inventively prepared and described above Preparations may additionally be increased by adding more plant extracts, especially from Melissa spec., Such as Melissa officinalis (melissa) and / or Hypericum spec., such as Hypericum perforatum (St. John's wort) are included.
Mit dem Phagotest® und Bursttest® (ORPEGEN Pharma, Heidelberg) wurden von gesunden Probanden Vollblutproben auf die Beeinflussbarkeit der Phagozytoseaktivität (Hirt, W., T. Nebe, and C. Birr. 1994. [Phagotest and Bursttest (Phagoburst), test kits for study of phagocyte functions]. Wien. Klin. Wochenschr. 106: 250–252) der in ihnen enthaltenen Granulozyten und Monozyten durch Echinacea einerseits und durch ein Alkalithiocyanat-Gemisch andererseits untersucht. Bei Echinacea handelte es sich um Frischpflanzen-Presssaftpulver, Rohmaterial Echinaceae purpureae herba recens (Firma Paninkret, Pinneberg). Beim Alkalithiocyanat-Gemisch handelte es sich um ein Gemisch von 60 Teilen Natriumthiocyanat und 40 Teilen Kaliumthiocyanat. Die eingesetzten Konzentrationen wurden auf Thiocyanat-Ionen berechnet. Neben diesen beiden Grundfaktoren, die beide für sich immunstimulierende Eigenschaften besitzen, wurden Gemische von beiden geprüft. Dem vorausgegangen erfolgte eine Testung der Reaktivität der Probanden gegenüber Echinacea. In dem auf diesem Weg herausgefundenen Konzentrationsbereich erfolgte die Testung der Gemische. Da davon ausgegangen werden konnte, dass Echinacea einerseits und Thiocyanat andererseits unterschiedliche Zellfunktionen anregen, ist auch ein additives Ergebnis als vorteilhaft einzuordnen. Von Echinacea-Zubereitungen ist ein unspezifischer Reiz zu erwarten, den man nur in angemessener Konzentration bzw. Dosierung nutzbar machen kann (Bauer, R. 2002. [New knowledge regarding the effect and effectiveness of Echinacea purpurea extracts] Wien. Med. Wochenschr. 152: 407–411; Bauer, V. R., K. Jurcic, J. Puhlmann, and H. Wagner. 1988. [Immunologic in vivo and in vitro studies on Echinacea extracts] Arzneimittelforschung. 38: 276–281).With the Phagotest ® and burst test ® (ORPEGEN Pharma, Heidelberg) were obtained from healthy volunteers whole blood samples to the suggestibility of phagocytic activity (Hirt, W., T. Nebe, and C. Birr 1994.. [Phagotest and burst test (Phagoburst), test kits Wien. Klin. Wochenschr., 106: 250-252) of the granulocytes and monocytes contained in them by Echinacea on the one hand and by an alkali thiocyanate mixture on the other. Echinacea was fresh-pressed vegetable juice powder, raw material Echinaceae purpureae herba recens (Paninkret, Pinneberg). The alkali thiocyanate mixture was a mixture of 60 parts of sodium thiocyanate and 40 parts of potassium thiocyanate. The concentrations used were calculated on thiocyanate ions. In addition to these two basic factors, both of which possess immunostimulatory properties, mixtures of both were tested. This was preceded by a test of the reactivity of the subjects against Echinacea. In the concentration range found in this way, the mixtures were tested. Since it could be assumed that Echinacea on the one hand and thiocyanate on the other stimulate different cell functions, an additive result is also to be classified as advantageous. Echinacea preparations are expected to have a nonspecific stimulus that can only be used in appropriate concentrations or doses (Bauer, R. 2002. [New knowledge concerning the effect and effectiveness of echinacea purpurea extracts], Vienna Bauer, VR, K. Jurcic, J. Puhlmann, and H. Wagner, 1988. Immunologic in Vivo and In Vitro Studies on Echinacea extracts Drug Research, 38: 276-281.
Vom Thiocycanat ist bekannt, dass es eine multifaktorielle essentielle Bedeutung im Zellstoffwechsel hat.from Thiocycanate is known to be a multifactorial essential Has significance in cell metabolism.
Ausführungsbeispiele:EXAMPLES
Beispiel 1example 1
Ergebnisse des PhagotestResults of the phagotest
Im Phagotest wurde die Phagozytoseaktivität des Vollblutes bestimmt. Dazu wurden mit Fluoreszeinisothiocyanat markierte E. coli's mit phagozytierenden Zellen des Vollblutes bei 37°C inkubiert und die Phagozytoseaktivität als Fluoreszenzsignal direkt erfasst. Die Kontrollen verblieben bei 0°C. Die Quantifizierung erfolgte mittels Durchflusszytometrie als prozentuale Bindung und mittlere Fluoreszenzintensität. Ausgewertet wurden Granulozyten und Monozyten.in the Phagotest the phagocytic activity of the whole blood was determined. These were fluorescein isothiocyanate labeled E. coli's with phagocytic Cells of whole blood at 37 ° C incubated and the phagocytosis activity as a fluorescence signal directly detected. The controls remained at 0 ° C. The quantification took place by flow cytometry as percent binding and mean Fluorescence intensity. Granulocytes and monocytes were evaluated.
Fallbeispiel
1
Fallbeispiel
2
Beispiel 2Example 2
Ergebnisse des BursttestResults of the burst test
Der Bursttest diente der Quantifizierung der oxidativen Burstaktivität von Monozyten und Granulozyten im heparinisierten Vollblut. Heparinisiertes Blut wurde mit den Testsubstanzen inkubiert. Nach Stimulation bildeten Granulozyten und Monozyten reaktive Sauerstoffradikale (Superoxidanion, Wasserstoffperoxid), welche die Bakterien im Phagosom zerstören. Die Bildung der Sauerstoffradikale wurde durch die Oxidierung des Farbstoffes Dihydrorhodamin erfasst, der in der oxidierten Form fluoresziert. Die Quantifizierung erfolgte mittels Durchflusszytometrie als prozentuale Bindung und mittlere Fluoreszenzintensität. Ausgewertet wurden Granulozyten und Monozyten.Of the Burst test was used to quantify the oxidative burst activity of monocytes and granulocytes in heparinized whole blood. Heparinized blood was incubated with the test substances. After stimulation formed Granulocytes and monocytes reactive oxygen radicals (superoxide anion, Hydrogen peroxide), which destroy the bacteria in the phagosome. The Formation of the oxygen radicals was due to the oxidation of the dye Dihydrorhodamine detected, which fluoresces in the oxidized form. The quantification was carried out by flow cytometry as a percentage Binding and mean fluorescence intensity. Granulocytes were evaluated and monocytes.
Fallbeispiel
1
Claims (14)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004005788A DE102004005788A1 (en) | 2004-02-06 | 2004-02-06 | Preparations containing Echinacea extracts and thiocyanate |
| EP05707911A EP1725248A1 (en) | 2004-02-06 | 2005-02-01 | Preparations containing echinacea extracts and thiocyanate |
| PCT/EP2005/050437 WO2005074955A1 (en) | 2004-02-06 | 2005-02-01 | Preparations containing echinacea extracts and thiocyanate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004005788A DE102004005788A1 (en) | 2004-02-06 | 2004-02-06 | Preparations containing Echinacea extracts and thiocyanate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE102004005788A1 true DE102004005788A1 (en) | 2005-09-01 |
Family
ID=34813149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE102004005788A Ceased DE102004005788A1 (en) | 2004-02-06 | 2004-02-06 | Preparations containing Echinacea extracts and thiocyanate |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1725248A1 (en) |
| DE (1) | DE102004005788A1 (en) |
| WO (1) | WO2005074955A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0236610A1 (en) * | 1986-03-13 | 1987-09-16 | Laclede Professional Products, Inc. | Enzymatic bandages and pads |
| CA2317067A1 (en) * | 1998-01-06 | 1999-07-15 | The Procter & Gamble Company | Antimicrobial peroxy acid oral care compositions and methods |
| US20030170322A1 (en) * | 2000-06-21 | 2003-09-11 | Shigeto Kayane | Throat care agents |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH676931A5 (en) * | 1988-08-02 | 1991-03-28 | Spagyros S A | Herbal medicaments prodn. - contg. essential antimicrobial oils and Echinacea tinctures, for treating infections, etc. |
| US6355684B1 (en) * | 1990-10-11 | 2002-03-12 | Meryl J. Squires | Antimicrobial treatment for herpes simplex virus and other infectious diseases |
| AT506U1 (en) * | 1994-11-22 | 1995-12-27 | Erber Erich Kg | FEEDING MATERIALS DRINKING WATER ADDED TO IMPROVE THE STRESS RESISTANCE AND IMMUNITY OF FARM ANIMALS |
| DE19710068A1 (en) * | 1997-03-12 | 1998-09-17 | Kramer Axel | Oral hygiene and oral health promoters |
| US5770217A (en) * | 1997-07-02 | 1998-06-23 | Atlatl, Inc. | Dietary supplement for hematological, immune and appetite enhancement |
-
2004
- 2004-02-06 DE DE102004005788A patent/DE102004005788A1/en not_active Ceased
-
2005
- 2005-02-01 WO PCT/EP2005/050437 patent/WO2005074955A1/en not_active Ceased
- 2005-02-01 EP EP05707911A patent/EP1725248A1/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0236610A1 (en) * | 1986-03-13 | 1987-09-16 | Laclede Professional Products, Inc. | Enzymatic bandages and pads |
| CA2317067A1 (en) * | 1998-01-06 | 1999-07-15 | The Procter & Gamble Company | Antimicrobial peroxy acid oral care compositions and methods |
| US20030170322A1 (en) * | 2000-06-21 | 2003-09-11 | Shigeto Kayane | Throat care agents |
Non-Patent Citations (5)
| Title |
|---|
| CA 2317067 A1 |
| JP 03118308 A (abstr.). In: Pat. Abstr. of Jp., [CD-ROM] * |
| Rosin M. et al.:Effect of a SCN-/H2O2 combinations in dentrifices on plaque and gingivitis. In:J Clin Periodontol. 2001 Mar., 28(3), S. 270-6 [online] [rech. am 26.10.04]. Im Internet: PubMed Accession No. 11284542 http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?SUBMIT=y |
| Rosin M. et al.:Effect of a SCN-/H2O2 combinationsin dentrifices on plaque and gingivitis. In:J ClinPeriodontol. 2001 Mar., 28(3), S. 270-6 [online] [rech. am 26.10.04]. Im Internet: PubMed AccessionNo. 11284542 http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?SUBMIT=y * |
| Rosin M. et al.:The effect of a SCN-/H2O2 tooth- paste compared to a commercially available tri- closan-containing toothpaste on oral hygiene and gingival health-a 6- month home-use study. In: J Clin Periodontol. 2002 Dec., 29(12), S. 1086-91 [online][rech. am 26.10.04]. Im Internet: PubMed Accession No. 12492909 http://www.ncbi.nlm.nih. gov/entrez/query.fcgi?SUBMIT=y * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1725248A1 (en) | 2006-11-29 |
| WO2005074955A1 (en) | 2005-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1658041B1 (en) | Body care product containing porous silver particles | |
| DE69935522T2 (en) | COSMETIC OR DERMOPHARMETTIC USE OF PEPTIDES FOR WOUND HEALING, HYDRATIZATION, IMPROVEMENT OF SKIN OVERHEAD IN NATURAL OR ACCELERATED AGING (HELIODERMIA, ENVIRONMENTAL POLLUTION) | |
| EP1658040B1 (en) | Silver-and zinc-containing product | |
| DE69224024T2 (en) | TORF-DERIVATED BIOACTIVE PRODUCTS AND THEIR CONTAINING PHARMACEUTICAL AND COSMETIC COMPOSITIONS | |
| DE2207294C2 (en) | Topical ointment base | |
| DE60034898T2 (en) | Antiallergic composition containing OLIGOSACCHARIDs and a saponin or basic amino acid for topical administration or inhalation | |
| EP0037488B1 (en) | Pharmaceutical composition for healing inflammatory and/or degenerative and/or atrophic mucous membranes | |
| EP0914138B1 (en) | Complex preparations characterised by a betain content | |
| DE69013671T2 (en) | Composition containing barium sulfate colloidal dispersion. | |
| EP2886131B1 (en) | Transparent gel | |
| DE102004005788A1 (en) | Preparations containing Echinacea extracts and thiocyanate | |
| DE1149858B (en) | Skin and hair care products | |
| CN116407478A (en) | Mild acne-removing composition and application thereof | |
| DE3816442A1 (en) | AGENTS FOR TREATING MYCOTIC, MICROBIC AND OTHER TISSUE-DAMAGING AND PATHOLOGICAL MANIFESTATIONS AND TISSUE INFORMATION | |
| WO2005023212A1 (en) | Skin cream | |
| DD297062A5 (en) | METHOD FOR PRODUCING A NOVEL TOPICAL DERMATIVE WITH ANTI-TESTING EFFECT | |
| DE1492023C3 (en) | Skin care products | |
| DE4429735A1 (en) | Agent for the treatment of immunobiological cell load deficiencies and method for its production | |
| DE19743622C2 (en) | Dental underfill material | |
| DE10132936B4 (en) | Use of galloylated proanthocyanidin | |
| AT516952B1 (en) | drug | |
| CH492593A (en) | Skin care products | |
| EP2130545A2 (en) | Solution and tincture | |
| DE102016107563A1 (en) | vitamin preparation | |
| DE3835864C2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8131 | Rejection |